MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
1. MBX 4291's Phase 1 trial for obesity has commenced. 2. Positive preclinical results indicate potential for superior weight loss solutions. 3. Once-monthly dosing may enhance patient adherence and tolerability. 4. Topline results from the trial are expected in 2027. 5. MBX 4291 aims to address significant unmet medical needs in obesity.